Akebia Therapeutics, Inc.
AKBA
$0.88
$0.044.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -21.36% | -6.61% | 23.93% | 57.01% | 43.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.36% | -6.61% | 23.93% | 57.01% | 43.13% |
| Cost of Revenue | -10.60% | 19.82% | 34.56% | 73.66% | 29.13% |
| Gross Profit | -23.59% | -11.00% | 21.67% | 53.88% | 46.41% |
| SG&A Expenses | 6.09% | 18.23% | -5.73% | 9.72% | -1.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.30% | 26.03% | 12.50% | 8.78% | -6.92% |
| Operating Income | -118.89% | -110.82% | 40.11% | 135.58% | 272.51% |
| Income Before Tax | -3,678.14% | -246.07% | 50.73% | 105.76% | 102.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,706.48% | -248.13% | 46.31% | 102.69% | 102.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,706.48% | -248.13% | 46.31% | 102.69% | 102.88% |
| EBIT | -118.89% | -110.82% | 40.11% | 135.58% | 272.51% |
| EBITDA | -114.45% | -108.23% | -659.55% | 252.25% | 1,124.05% |
| EPS Basic | -3,766.67% | -230.38% | 55.80% | 102.10% | 102.20% |
| Normalized Basic EPS | -1,600.00% | -180.24% | 61.21% | 104.54% | 103.32% |
| EPS Diluted | -3,766.67% | -230.38% | 53.80% | 102.00% | 102.20% |
| Normalized Diluted EPS | -1,600.00% | -182.72% | 61.21% | 104.37% | 103.32% |
| Average Basic Shares Outstanding | 2.68% | 13.40% | 21.34% | 25.88% | 25.21% |
| Average Diluted Shares Outstanding | -0.55% | 10.53% | 21.34% | 30.44% | 29.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |